Trial · NCT06145308
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06145308, Phase 2, Recruiting, Peking Union Medical College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing. Trials, record NCT06145308. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06145308
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
- NCT number
- NCT06145308
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 39 participants, estimated
- Lead sponsor
- Peking Union Medical College
- Conditions
- Salivary Gland Carcinoma, Precision Therapy
- Interventions
Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone), TROP2 ADC, TKI, Albumin-paclitaxel + platinum, Albumin-paclitaxel + carboplatin + apatinib + camrelizumab, albumin-bound paclitaxel+trastuzumab+pyrotinib, HER2,trastuzumab deruxtecan± pertuzumab, AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab, AR,AR antagonist +goserelin +docetaxel, ivonescimab + investigator-choice platinum doublet+, iparomlimab + tuvonralimab, cadonilimab, CDK4/6 inhibitor+AI or fulvestrant, alpelisib+fulvestrant, PARP inhibitor, enfortumab vedotin, HER2, pyrotinib + pertuzumab/trastuzumab, vebecotutamab ±lenvatinib
- First posted
- 2023-11-24
- Last updated
- 2026-04-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR | ORR at the end of Cycle 2 (each cycle is 21 days) | ORR rates for neoadjuvant and translational therapy in patients with locally advanced/recurrent and advanced oligometastatic salivary gland cancer and ORR rate of salvage therapy for locally advanced/recurrent or distantly metastatic salivary gland carcinoma with rapid progression that cannot tolerate or refuses surgery |
| Secondary | MPR; | MPR rate at the end of surgical treatment | MPR rates in patients who received neoadjuvant and translational therapy and then underwent surgery |
| Secondary | R0 resection rate; | R0 resection rate at the end of surgical treatment | R0 resection rate in patients who received neoadjuvant and translational therapy and then underwent surgery |
| Secondary | Facial nerve protection rate | Facial nerve protection rate at the end of surgical treatment | Facial nerve protection rate in patients who received neoadjuvant and translational therapy and then underwent surgery |
| Secondary | DFS | DFS rates at 3-year | 3-year DFS rates for patients who underwent surgery |
| Secondary | PFS; | PFS Rate at 2-Year | 2-Year PFS Rate for Patients Receiving Rescue Therapy |
| Secondary | OS | OS rate at 5-year | OS for all patients |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06145308
GET https://conductscience.org/api/trials/v1/NCT06145308/registered